Tucker Kelly
Fortuna: - $ al 31/05/2026
Fortuna: - $ al 31/05/2026
Thomas P.
Kelly is currently Chief Financial Officer at Xenon Pharmaceuticals, Inc. since 2025.
Formerly, Chief Financial Officer at Deciphera Pharmaceuticals, Inc. from 2015 to 2019, Chief Financial Officer at AdvanDx, Inc. from 2012 to 2015, Chief Financial Officer at deCODE Genetics ehf from 2010 to 2011, Chief Financial Officer and SVP-Finance & Corporate Development at Critical Therapeutics, Inc. from 2007 to 2008, Principal at Canaccord Adams, Inc. from 2003 to 2007, Vice President-Life Sciences Investment Banking at Robertson Stephens, Inc. from 1998 to 2002, and Associate at Foley Hoag LLP from 1996 to 1998.
Education includes graduate studies at The University of Chicago Law School and undergraduate studies at Edmund A. Walsh School of Foreign Service.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 15/10/2025 | 0 ( -.--% ) | - $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| XENON PHARMACEUTICALS INC. | Director Financiero/CFO | 15/10/2025 |
| Empresas | Cargo | Fin |
|---|---|---|
AdvanDx, Inc.
AdvanDx, Inc. Medical SpecialtiesHealth Technology Provides advanced molecular diagnostic products for the prevention, diagnosis and treatment of life-threatening, bacterial infections | Director Financiero/CFO | 16/03/2015 |
deCODE Genetics ehf
deCODE Genetics ehf Miscellaneous Commercial ServicesCommercial Services Provides research services with focus on human genes | Director Financiero/CFO | 01/01/2011 |
Critical Therapeutics, Inc.
Critical Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes products for respiratory, inflammatory and critical care diseases | Director Financiero/CFO | 04/11/2008 |
Canaccord Adams, Inc.
Canaccord Adams, Inc. Investment Banks/BrokersFinance Provides brokerage services | Corporate Officer/Principal | 01/08/2007 |
Robertson Stephens, Inc.
Robertson Stephens, Inc. Investment Banks/BrokersFinance Brokerage | Corporate Officer/Principal | 01/07/2002 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 11 |
|---|---|
Canaccord Adams, Inc.
Canaccord Adams, Inc. Investment Banks/BrokersFinance Provides brokerage services | Finance |
Critical Therapeutics, Inc.
Critical Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes products for respiratory, inflammatory and critical care diseases | Health Technology |
Xenon Pharmaceuticals, Inc.
Xenon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovering, developing and delivering of therapeutics for neurological & psychiatric disorders | Health Technology |
Foley Hoag LLP
Foley Hoag LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Robertson Stephens, Inc.
Robertson Stephens, Inc. Investment Banks/BrokersFinance Brokerage | Finance |
AdvanDx, Inc.
AdvanDx, Inc. Medical SpecialtiesHealth Technology Provides advanced molecular diagnostic products for the prevention, diagnosis and treatment of life-threatening, bacterial infections | Health Technology |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Discovers and develops pharmaceutical preparations | Health Technology |
deCODE Genetics ehf
deCODE Genetics ehf Miscellaneous Commercial ServicesCommercial Services Provides research services with focus on human genes | Commercial Services |
The University of Chicago Law School
The University of Chicago Law School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Edmund A. Walsh School of Foreign Service
Edmund A. Walsh School of Foreign Service Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel drug candidates to improve the lives of cancer patients | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.